1. Home
  2. PERI vs ALLO Comparison

PERI vs ALLO Comparison

Compare PERI & ALLO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PERI
  • ALLO
  • Stock Information
  • Founded
  • PERI 1999
  • ALLO 2017
  • Country
  • PERI Israel
  • ALLO United States
  • Employees
  • PERI N/A
  • ALLO N/A
  • Industry
  • PERI EDP Services
  • ALLO Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • PERI Technology
  • ALLO Health Care
  • Exchange
  • PERI Nasdaq
  • ALLO Nasdaq
  • Market Cap
  • PERI 395.5M
  • ALLO 438.2M
  • IPO Year
  • PERI 2006
  • ALLO 2018
  • Fundamental
  • Price
  • PERI $8.87
  • ALLO $1.82
  • Analyst Decision
  • PERI Hold
  • ALLO Strong Buy
  • Analyst Count
  • PERI 5
  • ALLO 10
  • Target Price
  • PERI $10.17
  • ALLO $10.06
  • AVG Volume (30 Days)
  • PERI 315.9K
  • ALLO 3.1M
  • Earning Date
  • PERI 02-05-2025
  • ALLO 03-13-2025
  • Dividend Yield
  • PERI N/A
  • ALLO N/A
  • EPS Growth
  • PERI N/A
  • ALLO N/A
  • EPS
  • PERI 0.93
  • ALLO N/A
  • Revenue
  • PERI $602,939,000.00
  • ALLO $43,000.00
  • Revenue This Year
  • PERI N/A
  • ALLO N/A
  • Revenue Next Year
  • PERI N/A
  • ALLO N/A
  • P/E Ratio
  • PERI $9.57
  • ALLO N/A
  • Revenue Growth
  • PERI N/A
  • ALLO 26.47
  • 52 Week Low
  • PERI $7.47
  • ALLO $1.78
  • 52 Week High
  • PERI $31.38
  • ALLO $5.78
  • Technical
  • Relative Strength Index (RSI)
  • PERI 56.56
  • ALLO 36.69
  • Support Level
  • PERI $8.73
  • ALLO $2.11
  • Resistance Level
  • PERI $9.07
  • ALLO $2.10
  • Average True Range (ATR)
  • PERI 0.26
  • ALLO 0.17
  • MACD
  • PERI 0.03
  • ALLO -0.02
  • Stochastic Oscillator
  • PERI 65.35
  • ALLO 5.69

About PERI Perion Network Ltd.

Perion Network Ltd is a technology company. It offers online advertising and search solutions to brands, agencies, and publishers through desktop, mobile, and social channels. It connects advertisers to consumers across digital advertising channels, including search advertising, social, display, video, digital audio, digital out of home (DOOH), and Connected TV (CTV) advertising. The company earns prime revenue from search advertising and display advertising services. It operates in the business segment of High Impact Advertising solutions. Geographically, the company generates a majority of its revenue from the United States and the rest from other regions.

About ALLO Allogene Therapeutics Inc.

Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, primarily generated from collaborations and licensing agreements, supports their research and development efforts.

Share on Social Networks: